DSS (DSS) investor relations material

Company overview and business model

• Operates as a multi-segment company with divisions in packaging, biotechnology, commercial lending, and securities/investment management.

• Product Packaging segment provides custom packaging and security printing solutions, primarily through Premier Packaging Corporation.

• Biotechnology segment includes investments and development via DSS BioHealth Security and Impact BioMedical Inc., focusing on drug platforms and healthcare technologies.

• Commercial Lending segment, through American Pacific Financial, offers financing solutions such as lines of credit, equipment financing, and loan servicing.

• Securities and Investment Management segment manages interests in brokerage, investment management, and real estate investment platforms.

Financial performance and metrics

• Reported year-over-year revenue growth and increased printed product sales in Q1 2025.

• Completed sale of Plano, Texas facility for $9.5 million, using part of proceeds to reduce debt.

• As of December 31, 2025, had $17.0 million in net intangible assets, mainly from Impact BioMedical.

• Significant indebtedness includes loans with Bank of America, Patriot Bank, Pinnacle Bank, and convertible notes with Alset entities.

• One customer accounted for 29% of consolidated revenue as of December 31, 2025.

Use of proceeds and capital allocation

• Estimated net proceeds of $7,050,000 (assuming full sale at $0.96/share), after $950,000 in offering expenses.

• Proceeds intended for working capital, general corporate purposes, R&D, capital expenditures, and potential acquisitions or investments.

• No current commitments for acquisitions or investments as of the filing date.